Molecular Pharmacology of VEGF-A Isoforms: Binding and Signalling at VEGFR2.
Peach CJ, Mignone VW, Arruda MA, Alcobia DC, Hill SJ, Kilpatrick LE, Woolard J. · 2018
Read Molecular Pharmacology of VEGF-A Isoforms: Binding and Signalling at VEGFR2. by Peach CJ, Mignone VW, Arruda MA, Alcobia DC, Hill SJ, Kilpatrick LE, Woolard J. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5979509.txt.
Introduction
Peach and co-authors review the molecular pharmacology of VEGF-A isoforms at the VEGFR2 receptor. Their review appeared in the International Journal of Molecular Sciences. VEGF-A is a key driver of new blood vessel growth. It signals mainly through VEGFR2 on vessel lining cells. Splicing of one gene yields many isoform variants. They differ in availability and in partner binding. Yet they bind the receptor with similar strength.
How isoforms signal so distinctly is the central puzzle. The review re-checks the pro-growth label of the classic form. It covers control by other membrane and matrix proteins. Better grasp of isoform action may guide future drugs.
Catalog record
| CREATOR | Peach CJ, Mignone VW, Arruda MA, Alcobia DC, Hill SJ, Kilpatrick LE, Woolard J. |
|---|---|
| YEAR | 2018 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 94 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Molecular Pharmacology of VEGF-A Isoforms: Binding and Signalling at VEGFR2 By Chloe J. Peach, Viviane W. Mignone, Maria Augusta Arruda, Diana C. Alcobia, Stephen J. Hill, Laura E. Kilpatrick, Jeanette Woolard Published in: International Journal of Molecular Sciences DOI: 10.3390/ijms19041264 ABSTRACT Vascular endothelial growth factor-A (VEGF-A) is a key mediator of angiogenesis, signalling via the class IV tyrosine kinase receptor family of VEGF Receptors (VEGFRs). Although VEGF-A ligands bind to both VEGFR1 and VEGFR2, they primarily signal via VEGFR2 leading to endothelial cell proliferation, survival, migration and vascular permeability. Distinct VEGF-A isoforms result from alternative splicing of the Vegfa gene at exon 8, resulting in VEGFxxxa or VEGFxxxb isoforms. Alternative splicing events at exons 5–7, in addition to recently identified posttranslational read-through events, produce VEGF-A isoforms that differ in their bioavailability and interaction with the co-receptor Neuropilin-1. This review explores the molecular pharmacology of VEGF-A isoforms at VEGFR2 in respect to ligand binding and downstream signalling. To understand how VEGF-A isoforms have distinct signalling despite similar affinities for VEGFR2, this review re-evaluates the typical classification of these isoforms relative to the prototypical, “pro-angiogenic” VEGF165a. We also examine the molecular mechanisms underpinning the regulation of VEGF-A isoform signalling and the importance of interactions with other membrane and extracellular matrix proteins. As approved therapeutics targeting the VEGF-A/VEGFR signalling axis largely lack long-term efficacy, understanding these isoform-specific mechanisms could aid future drug discovery efforts targeting VEGF receptor pharmacology. 1. INTRODUCTION Angiogenesis is the formation of new blood vessels by the sprouting of endothelial cells from pre-existing vasculature [1]. While vasculogenesis (formation of angioblast-derived blood vessels) occurs mainly during embryonic development, angiogenesis takes place throughout adult life [2,3], playing a vital role in physiological events such as wound repair [4], the oestrous cycle and placentation [5]. In addition to its importance in normal physiology, angiogenesis is also a key feature associated not only with cancer [6], but also with several pathological conditions including age-related macular degeneration [7], rheumatoid arthritis [8], psoriasis [9], diabetes-induced ocular neovascularisation [10], inflammatory diseases [11], ischaemia/reperfusion injury [12], infantile haemangioma and atherosclerosis [13,14]. Despite their distinct aetiologies, these disorders can be characterised as angiogenesis-dependent diseases [15] and are either caused or exacerbated by an imbalance between the production/activity of anti- and pro-angiogenic factors [16]. Among the pro-angiogenic endogenous molecules, vascular endothelial growth factor (VEGF) is a major regulator of blood vessel formation in health and disease [1]. Initially, VEGF was termed vascular permeability factor (VPF) due to its ability to increase the permeability of blood vessels [17,18]. Following subsequent observations of the additional effects of VPF on endothelial cells and concomitant cloning, VPF was renamed VEGF [19]. The VEGF family of proteins comprises VEGF-A, VEGF-B [20], VEGF-C, VEGF-D, Placental Growth Factor (PlGF) [21], the virus-encoded VEGF-E and the snake venom-derived VEGF-F [22,23,24]. VEGF-A is the best characterised family member being the most potent stimulator of angiogenic processes and therefore a target of numerous anti-cancer therapeutics [25]. VEGF-A is a large anti-parallel homodimeric peptide that belongs to the “Cys-loop” superfamily of proteins, based on a central knot motif of cysteine residues that form intramolecular disulphide bonds when assembled into a folded structure [24,26]. VEGF-A is secreted by many cell types such as endothelial cells [27,28], fibroblasts [29], smooth muscle cells [30], platelets [31], neutrophils [32], macrophages and approximately 60% of all tumours [33]. VEGF-A secretion is also induced by ischemia and inflammatory stimuli [34]. Cellular responses to VEGF-A are mainly driven by their binding to their cognate receptor—the vascular endothelial growth factor receptors (VEGFRs). VEGFRs belong to the class IV receptor tyrosine kinase (RTK) family [35] and show similarities to type III RTKs platelet derived growth factor receptor (PDGFR), macrophage colony stimulating factor receptor (M-CSFR), c-KIT and fms-like tyrosine kinase 3 (FLT3) [36]. There are three VEGFR subtypes which are encoded by separate genes: VEGFR1 (Flt-1 in mice) and VEGFR2 (Flk-1; KDR) are structurally similar, whereas VEGFR3 (Flt-4) has a proteolytically processed extracellular domain [37,38]. VEGFRs are expressed by endothelial cells, macrophages, hematopoietic cells and smooth muscle cells [39,40,41]. Signalling of VEGF-A isoforms via VEGFR1 and VEGFR2 drive physiological and pathophysiological angiogenesis, whereas lymphangiogenesis is mediated by VEGF-C/D isoforms via VEGFR3 [42]. Although VEGFR1 has a higher affinity for VEGF-A than VEGFR2, it shows decreased tyrosine kinase activity and is therefore largely considered a decoy receptor that can negatively modulate VEGFR2 activity [43,44]. While VEGFR1 also plays a role in immune cell differentiation [45,46], VEGFR1 is beyond the scope of this review (reviewed in [47]). Alternative splicing of the Vegfa gene leads to different VEGF-A isoforms which have been proposed to promote distinct signalling outcomes [16]. Through quantifying and comparing the pharmacology of VEGF-A isoforms at VEGFR2, we can begin to comprehend how they differ as distinct endogenous ligands. This could ultimately enable better understanding of molecular mechanisms that give rise to distinct physiological outcomes with relevance in health and disease [16] and future drug discovery efforts [25]. In this review, we have explored in detail the molecular pharmacology of VEGF-A isoforms in terms of their receptor binding to VEGFR2 and downstream signalling with particular reference to the influence of agonist efficacy and signalling coupling on physiological outcomes. 2. GENERATION OF VEGF-A ISOFORMS BY ALTERNATIVE SPLICING The regulation of vascular supply relies on tight regulation between factors that promote (pro-angiogenic) or inhibit (anti-angiogenic) vessel development, via a mechanism that is reactive to changes in oxygen and nutrient levels. VEGF-A transcription is affected by the local cellular environment, such as during hypoxia [48,49] following secretion of growth factors, cytokines and hormones, shear stress, genotoxic agents [50] and the activity of both oncogenes and tumour suppressor genes [51]. The human Vegfa gene is located on chromosome 6p21.1 [52], with a coding region spanning approximately 14 kilobases consisting of eight exons and seven introns. Alternative splicing of this pre-mRNA selectively removes intron regions and joins specific combinations of exons to generate distinct VEGF-A isoforms [53] (Figure 1). Alternative splicing is advantageous in expanding the repertoire of possible VEGF-A isoforms that can be produced from a single gene [54]. These isoforms differ in respect to their length and are designated VEGFxxx, where xxx represents the number of amino acids present in the final protein sequence. To date 16 distinct VEGFA isoforms have been identified most commonly from six transcripts: VEGF111, VEGF121, VEGF145, VEGF165, VEGF189, and VEGF206 [16,55,56]. An additional isoform, VEGF-Ax, was also identified in 2014 that arises from programmed translational read-through (PTR) [56]. VEGF165a was the first isoform characterised and remains the most extensively investigated in respect to its function, signalling, expression and pathological roles [19]. As a potent stimulator of angiogenesis, VEGF165a is considered the prototypical pro-angiogenic VEGF-A isoform. Altered VEGF-A isoform expression has been well documented in tissues during physiological and/or pathological conditions [57,58,59,60,61]. Boundaries between exons are defined by splicing sites which are recognised by a dynamic complex of proteins located in the nucleus called the spliceosome [62], containing five small nuclear ribonucleoproteins (snRNPs)—U1, U2, U4, U5 and U6—plus associated accessory proteins U2AF and SF1. VEGF-A splicing is also regulated by a series of RNA binding proteins, most commonly the serine/arginine (SR) proteins, chiefly SRSF1, SRSF2, SRSF5 and SRSF6 [54]. SR proteins are phosphorylated in the cytoplasm at multiple serine/arginine and